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COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE
BOWEL SYNDROME AT THE SOCIAL SECURITY MEXICAN INSTITUTE
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1Universidad Nacional Autónoma de México, México City, Mexico, 2Instituto Mexicano del Seguro
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OBJECTIVES: Irritable Bowel Syndrome (IBS) is a chronic and relapsing sickness of
high economic impact on society and patients’ life quality. The purpose of this
study is to estimate the cost-effectiveness of treatment with otilonium bromide
(OB) compared with pinaverium bromide (PB) and hyoscine butilbromide (HB) in
the treatment of abdominal pain in patients with IBS from an institutional
perspective. METHODS: A cost-effectiveness analysis was developed using a
Markovmodeling approach: Themodel simulates cost and effectiveness outcomes
in a 6 month period for treatment of IBS with OB (40mg every 8 hrs); PB (10-20mg
every 8 hrs); and HB (50mg every 8 hrs). Three health conditions were considered
(“symptom control”, “continuing symptom profile” and “relapse”) with a 7-day
cycles. Effectiveness measures: clinic success rate and symptomless time. The
probabilities of transition were estimated from international random clinical.
Costs and resource use were collected from hospital records related to patients
with IBS at IMSS in 2010 (n150). The probabilistic sensitivity analysis was ob-
tained through a second-order Monte Carlo simulation RESULTS: The greatest
effectiveness of clinic improvement was shown by patients treated with OB (76%)
followed by those of PB (72%) andHB (66%). The greatest effectiveness in symptom-
less conditions was shown by OB (18 weeks) followed PB (17 weeks) and HB (15
weeks). Thus,mean cost per patientwere lowerwithOB (US$ 505.22) followed by PB
(US$530.74) and HB (US$642.71). Regarding the ICER, OB resulted the dominant
therapy. Acceptability curves showed OB as the most cost-effective therapy in
100% independently of IMSS willingness to pay. CONCLUSIONS: In Mexico, OB
represents the best cost-effective alternative since it offers greater control and
more symptomless weeks in patients with IBS. These results should be taken into
account by Mexican decision makers.
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RESOURCE UTILIZATION AND HEALTH CARE COSTS ASSOCIATED WITH
DIVERTICULAR DISEASE: RESULTS FROM A RETROSPECTIVE CLAIMS
DATABASE ANALYSIS IN THE UNITED STATES
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OBJECTIVES: To compare all-cause resource utilization and health care costs be-
tween patients with diverticular disease (DD) and matched controls. METHODS:
Medical and pharmacy claims data from the Ingenix IMPACT Managed Care data-
basewere analyzed (2005–2008,40 health plans, all geographic regionswithin the
US represented). Patients with DDwere defined as those with primary diagnosis of
colonic diverticulitis (1 claim) followed by acute antibiotic treatment within 3
days of diagnosis (n36,636); first diverticulitis claim defined study index date.
Controls from the same database werematched 2:1 based on age, gender, and plan
enrollment dates (n73,272); the index date was the date of their respectivematch
from the DD group. Study eligibility required plan enrollment for 6 months pre-
index and12months post-index. Outcomeswere evaluated over 12months post-
index. Generalized linear models and negative binomial regression models were
used to estimate resource utilization and health care costs. Costs were adjusted to
2009 dollars. RESULTS: Rates of resource utilization and health care costs were
significantly higher for DD patients than for controls: hospitalization, ER visits, and
office visits were 8-fold (Incidence Rate Ratio [IRR]8.1), 4-fold (IRR3.7), and 2-fold
(IRR2.3) higher, respectively, than in controls; all P0.0001. Due to higher resource
utilization, adjustedmean total annual all-cause costs were substantially higher in
DD patients than controls ($16,933 vs. $7,028; P0.0001). The major drivers for the
cost difference were hospitalizations ($6,554 vs. $1,374), ER visits ($1,022 vs. $120),
outpatient/ancillary costs ($4,289 vs. $2,168), and office visits ($2,280 vs. $1,420); all
P0.0001. CONCLUSIONS: The economic burden of patients with DD is significant,
with substantial costs occurring in cost sectors such as hospitalization, ER, and
office visits. Interventions are needed to reduce diverticulitis occurrences and po-
tentially decrease the costs associated with hospitalization, ER visits, and outpa-
tient/ancillary services. Supported by funding from Shire Development Inc.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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HCV TREATMENT CONTINUATION RATES IN GENOTYPE 1 PATIENTS IN A
REAL-WORLD SETTING IN THE UNITED STATES
Diels J, Gavart S, Nuyts G
Janssen Pharmaceutica, Beerse, Belgium
OBJECTIVES: Conventional antiviral therapy of treatment-naive genotype 1 hepa-
titis C virus (HCV)-infected patients consists of 48 weeks of pegylated interferon
and ribavirin combination. The purpose of this study was to document real-life
continuation rates to HCV therapy. METHODS: Commercially insured patients
with chronic HCV infection (ICD-9-codes 070.44,070.54, 070.70,070.71) with docu-
mented genotype 1 lab results were identified from a large US claims database
(Ingenix 2006–2009). Index date was treatment initiation of any combination of
(peg)interferon and/or ribavirin. Only genotype 1 patients with one year retrospec-
tive (pre-index) and prospective (post-index) available datawithout HCV treatment
in the retrospective yearwere included. Therapy discontinuationwas defined as an
observed refill gap of at least 56 days between two subsequent prescriptions. Time
to discontinuationwas analyzed using Kaplan-Meier andCox proportional hazards
regression. RESULTS: Of all patients with reported genotype, 82% (N332) were
genotype 1 patients. 95.2% initiated a combination of peginterferon and ribavirin.
Mean time on treatment was 261 days. 7.2% of all patients only had one prescrip-
tion without refill. For patients with at least one refill prescription, the hazard of
treatment discontinuation was constant over time. By week 24, 25.6% [95% CI 21.3–
30.7] had discontinued treatment, while 49.4% [43.9–54.6] of patients completed 48
weeks of therapy. Treatment discontinuations were not associated with age, gen-
der or co-morbidity. CONCLUSIONS:While a 48-week therapy for treatment-naive
genotype 1 patients is recommended with current standard of care to obtain sus-
tained viral response (SVR), we observed that in daily clinical practice 50.6% of the
patients discontinued therapy earlier. Low treatment continuation rates in real life
may result in lower SVR rates compared with what is observed in clinical trial
settings. Treatment completion ratesmay be higher with therapies allowing short-
ened treatment duration.
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FEASIBILITY OF ASSESSING UTILITY BY EQ-5D AND TIME-TRADE-OFF
METHODS IN TAIWANESE CHRONIC HEPATITIS B PATIENTS
Lin YT1, Chen LC2, Huang YB1, Huang JF3
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OBJECTIVES: The extent of difference regarding quality of life (QOL) according to
disease severity in chronic hepatitis B virus infection (CHB) has rarely been investi-
gated. The aim of the study was to explore the adaptation and appropriateness of
different utilitymeasures of QOL in Taiwanese CHBpatients.METHODS: Consecutive
adult CHB patientswho visited liver clinics at amedical center and a regional hospital
from July to December 2010were invited for interviews. Time-trade off (TTO), EuroQol
group 5-dimension (EQ-5D) questionnaire and 100-mm visual analogue scale (EQ-5D
VAS) were used to measure participations’ utility. The EQ-5D assessment was trans-
formed into EQ-5D index by using Japanese preference weight. Multivariate analysis
was used to evaluate the association between patients’ demography (age, marriage,
and employment status), Charlson comorbidity index and utility values. RESULTS: A
total of 120 patients (mean age48.0211.04 years, 85%male) were recruited, includ-
ing 20 patients of cirrhosis and 14 patients of hepatocellular carcinoma. The mean
utility andmeasurement success rates forEQ-5D index, EQ-5DVAS, andTTOwere0.83
 0.87 (98%), 0.89  0.14 (99%), and 0.65  0.29 (92%), respectively. The former two
utilities were significantly associated with employment status whilst TTO were sig-
nificantly associatedwithmarriage status. Therewas no difference in utility of EQ-5D
VAS, EQ-5D index and TTO between CHB patients (0.910.13, 0.770.14, 0.650.28),
CHB patients concomitantwith cirrhosis (0.86 0.16, 0.72 0.23, 0.69 0.32) and CHB
patients concomitant hepatocellular carcinoma (0.85  0.14, 0.71  0.20, 0.58  0.27).
CONCLUSIONS: EQ-5D questionnaire and EQ-5D VAS are feasible QOLmeasurement
inTaiwaneseCHBpatients. SinceTaiwanesepreferenceweight for transferring EQ-5D
assessment into EQ-5D index has not been established, further large-scale study is
needed to cross validate this measurement and explore the differences of QOL in
terms of disease severity.
PGI19
HEALTH-RELATED QUALITY OF LIFE IS LOWER FOR PATIENTS WITH DIURNAL
AND NOCTURNAL GERD SYMPTOMS
Goren A1, Gupta S2, Balu S3, Buchner D3
1Kantar Health, New York, NY, USA, 2Kantar Health, Princeton, NJ, USA, 3Eisai, Inc., Woodcliff
Lake, NJ, USA
OBJECTIVES: This study assessed whether health-related quality of life (HRQoL)
differed between respondents diagnosed with both diurnal and nocturnal gastro-
esophageal reflux disease (GERD) and those diagnosed with either type alone, or
non-diagnosed respondents.METHODS: Data were analyzed from Kantar Health’s
2010 National Health and Wellness Survey, a nationally representative dataset of
US adults (collected over three waves, January 7 to August 13). Outcome variables
were SF-12v2 mental and physical component summary (MCS and PCS) and SF6D
health utilities (measuring health status) scores. Lower scores indicate worse out-
comes. Analyses of covariance (ANCOVAs) predicted MCS, PCS, and SF6D from the
four GERD groups and a range of covariates. RESULTS: There were 75,000 respon-
dents: non-GERD (n68,593), diurnal (n710), nocturnal (n1,493), and diurnal-
and-nocturnal GERD (n4,204). Estimated means adjusted for the following cova-
riates (and others) at levels shown: gender (48% female); age (48.2); African
American (11%); Hispanic (6%); BMI: overweight (32%) and obese (33%); Charlson
comorbidity index, excluding ulcers (.397); and taking prescription for GERD (6%).
All groups exhibited significantly higher MCS scores than the diurnal-and-noctur-
nal GERD Group (MNon-GERD 48.6, SE 0.043;MDiurnal 47.5, SE 0.426;MNocturnal
47.4, SE  0.314; MDiurnal&Nocturnal  45.0, SE  0.249); higher PCS scores (MNon-GERD 
48.5, SE  0.038; MDiurnal  47.6, SE  0.377; MNocturnal  47.4, SE  0.278;
MDiurnal&Nocturnal  45.6, SE  0.220); and higher SF6D scores (MNon-GERD  0.752, SE 
0.001; MDiurnal  0.727, SE  0.005; MNocturnal  0.729, SE  0.004; MDiurnal&Nocturnal 
0.695, SE .003), all ps 0.001. CONCLUSIONS: Based on this analysis, respondents
with both diurnal-and-nocturnal GERD suffer poorer HRQoL than those with no
GERD, or only diurnal or nocturnal GERD. This suggests an unmet need to improve
medical care especially for those who have both diurnal and nocturnal GERD.
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OBJECTIVES: To assess symptoms reported by IBS-C patients through exploratory
open-ended questions in two phase 3 clinical trials.METHODS: Prior to answering
a daily symptom diary, patients were asked to list bothersome symptoms of IBS-C
in an open-ended manner at the pre-treatment visit. At the randomization visit,
patientswere asked to list any additional bothersome symptoms of IBS-C thatwere
not assessed during the prior two weeks. The data at both time points for random-
ized patients were analyzed using ATLAS.ti. Codes were developed using patients’
verbatimwords. Frequency counts of symptomswere tabulated. Resultswere com-
paredwith symptoms reported from four focus groupswith IBS-C patients (n 32).
RESULTS: Across trials, 1496/1610 (92.9%) and 603/1610 (37.5%) patients provided
responses at the pre-treatment and randomization visit, respectively. The ten
bothersome symptoms of IBS-C listed by patients most frequently at the pre-treat-
ment visit were: bloating (76.1%), cramping (39.0%), gas (31.6%), constipation
(29.1%), abdominal pain (24.8%), pain (general) (21.1%), fullness (20.0%), straining
(14.4%), pain (stomach) (13.4%), and UBM (13.1%). Out of the patients reporting
additional symptoms at randomization, the fivemost frequently listed bothersome
symptoms were: gas (23.1%), bloating (14.1%), cramping (12.9%), fullness (11.6%),
and nausea (11.6%). Only two of these symptoms identified at the randomization
visit were not assessed during the trial: gas and nausea. The symptoms most fre-
quently reported by patients in the trial were reported during the focus groups.
CONCLUSIONS: This method of data collection provided insight on IBS-C patient
perspective. Adult IBS-C patients experiencemany bothersome symptoms, includ-
ing both abdominal and bowel symptoms. The results from this analysis confirm
the comprehensiveness of four focus groups conducted with IBS-C patients and
provides evidence that across different IBS-C patient groups the type of abdominal
and bowel symptoms reported by patients is consistent.
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HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE
ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS’ TREATMENT WITH
MULTI-MATRIX MESALAMINE: COMPARISON WITH 2009 GENERAL
POPULATION NORMS IN THE UNITED STATES
Yarlas A1, Yen L2, Hodgkins P2
1QualityMetric Incorporated, Lincoln, RI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA
OBJECTIVES: Ulcerative colitis (UC) is a chronic inflammatory disease of the large
intestine and rectum. Symptoms such as abdominal pain, diarrhea, and the per-
sistent urge to defecate can impair UC patients’ physical and socio-psychological
well-being. This study examined themagnitude of this impairment, and the degree
towhich treatment improved health-related quality of life (HRQL), ofmild-to-mod-
erate UC patients relative to a US general population sample. METHODS: Short-
Form (SF)-12v2 baseline and endpoint scores were collected from a multicenter,
open-label study in which patients with active mild-to-moderate UC received
multi-matrix (MMX) mesalamine 2.4–4.8g/day QD for 8 weeks. Patients were com-
pared with a 2009 US general population sample derived from an Internet-based
survey administered to a representative national sample of adults. The normative
sample was matched to the age and sex of the patient sample using least squares
regression. Analysis of variance models tested for significant differences between
UC patients’ mean scores and normative sample’s estimated scores at each time.
Group comparisons onphysical andmental summary scores (PCS andMCS, respec-
tively) relative to established minimally significant differences (MID) of 3 points
identified clinically meaningful group differences. RESULTS: Baseline SF-12v2
scores for UC patients were significantly below thematched general population on
7 of 8 subscales (all P0.01 except formental health, P0.05) and on both summary
measures (PCS: 45.4 vs. 50.4, P0.001; MCS: 47.3 vs. 49.4, P0.05). Sample differ-
ences for PCS scores but not MCS scores exceeded the establishedMID. At 8 weeks,
SF-12v2 scores of the treated UC patients were either statistically equivalent to or
exceeded norm scores. CONCLUSIONS: Active UC negatively impacted almost all
dimensions of HRQL; the burden in physical health dimension was larger than the
burden in mental health. Eight weeks of daily MMX mesalamine treatment im-
proved patients to “normal” levels of functioning and well-being.
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CONCORDANCE AMONG MULTIPLE HEALTH OUTCOMES MEASURES IN
RESPONSIVENESS TO MULTI-MATRIX MESALAMINE MAINTENANCE
TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS
Yen L1, Yarlas A2, Hodgkins P1
1Shire Pharmaceuticals, Wayne, PA, USA, 2QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: To understand the correspondence across measures of patient-re-
ported outcomes (PRO) in quiescent ulcerative colitis (UC) patients, we examined
the responsiveness to treatment, sensitivity to disease activity, and inter-associa-
tions amongmeasures of generic and disease-specific health-related quality of life
(HRQL) and work-related outcomes. METHODS: Patients with UC in quiescence
(defined by a lack of rectal bleeding and normal frequency of defecation) received
2.4 g/day multi-matrix (MMX) mesalamine daily for 12 months in a multicenter,
prospective, open-label study. PROs were administered at baseline, 6 months, and
12 months. The Short Form (SF)-12v2 measured generic HRQL, the shortened In-
flammatory Bowel Disease Questionnaire (SIBDQ) measured IBD-specific HRQL,
and the Work Productivity and Activity Impairment Questionnaire for UC (WPAI:
UC) measured absenteeism and work productivity. Repeated-measures ANOVAs
examined changes in scores over time. Associations among instruments were as-
sessed by inter-subscale correlations. Sensitivity to disease activity was assessed
using ANCOVA models to compare PRO endpoint scores between recurrent and
non-recurrent patients (recurrence is defined as 4 or more bowel movements/day
above normal, and evidence of urgency, abdominal pain or rectal bleeding). Data
were collected at baseline, Month 6, andMonth 12/early withdrawal. RESULTS: 198
patients were enrolled at baseline. In quiescent patients, no changes in any PRO
instrument subscale occurred over time (all p0.10). Overall, small to moderate
inter-subscale correlationswere found across all instruments: average correlations
were 0.37 between SF-12v2 and SIBDQ subscales, 0.33 between SF-12v2 and
WPAI:UC subscales, and 0.43 between SIBDQ and WPAI:UC subscales. Most sub-
scales demonstrated statistically worse outcomes for patients with recurrent UC.
CONCLUSIONS: In quiescent UC patients, instruments measuring different out-
comes associated with UC showed stability during 12-month maintenance treat-
ment withMMXmesalamine. The strength of inter-scale correlations and the find-
ing of similar sensitivity to clinical outcomes indicate convergent validity among
these instruments within this patient population.
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WORK PRODUCTIVITY AMONG GENOTYPE 1 HEPATITIS C VIRUS (HCV)
TREATMENT-NAÏVE PATIENTS RECEIVING TELAPREVIR-BASED TREATMENT
REGIMENS: RESULTS FROM ADVANCE AND ILLUMINATE STUDIES
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Beumont M6, Gavart S2
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OBJECTIVES: ADVANCE and ILLUMINATE, phase 3 studies, evaluated efficacy and
safety of telaprevir (T)/peginterferon alfa-2a/ribavirin (PR) for genotype 1 HCV
treatment-naïve patients. ADVANCE patients were randomized to 8 or 12 weeks of
T/placebo plus PR (24 or 48 weeks) or PR (48 weeks). ILLUMINATE patients received
T plus PR for 12 weeks; those with extended rapid virologic response (eRVR) were
randomized to 24- or 48-week total treatment. We report on the patient self-re-
ported impact of telaprevir-based regimens on work productivity.METHODS: The
five-item Work Productivity Questionnaire (WPQ) was administered to patients
(N932) at day 1, and weeks 4, 12, 24, 36, 48 and 72 (assessed previous 4 weeks).
WPQ responses were tabulated at each timepoint by treatment group using de-
scriptive statistics.RESULTS:At baseline, daysmissed fromwork (mean, SD) due to
HCV or its treatment ranged from 0.8 (3.6) to 1.1 (4.4) days across treatment groups
(ADVANCE), and from 0.6 (3.1) to 0.7 (3.3) (eRVR groups, ILLUMINATE) and in-
creased 4-5 fold by week 12 in ADVANCE and ILLUMINATE. Compared to baseline,
more patients reportedworking shorter hours and being less productive byweek 12
in ADVANCE and in ILLUMINATE eRVR groups. At week 48, days missed from
work approached baseline levels in telaprevir treatment groups (1.1 [4.9] T12PR; 1.0
[4.7] T8PR) but not in PR (1.9 [6.3]); in ILLUMINATE corresponding values were 0.1
(0.5) in T12PR24 and 0.8 (2.3) in T12PR48. After week 12, other work productivity
measures improved earlier in telaprevir-based groups versus PR (ADVANCE), and
in T12PR24 versus T12PR48 in ILLUMINATE (eRVR). CONCLUSIONS:Among geno-
type 1 HCV treatment-naïve patients, work productivity decreased during the first
twelve weeks of therapy in all treatment arms. Work productivity, however, re-
turned to pre-treatment levels earlier in patients who received telaprevir-based
regimens compared with PR and in those patients who received shorter treatment
duration.
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DOES UTILITY OR CAPABILITY MATTER FOR IRRITABLE BOWEL SYNDROME? -
A PRELIMINARY QUALITATIVE STUDY ON TAIWANESE PATIENTS
Hsu CC1, Chen LC2, Wen YH1, Su YC3
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Nottingham, Nottingham, UK,
3Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gas-
trointestinal disorder with continuous nuisance bowel symptoms leading to long-
term disturbances on quality of life (QoL). Various conventional and innovative
gastrointestinal drugs are available for the symptomatic control of IBS. However, it
is uneasy to justify cost-effectiveness of IBS treatments due to the unspecific symp-
toms, a disparity of QoL measurements and a lack of clear association between
functioning and QoL. This preliminary used a qualitative approach to explore the
impacts of IBS on patients and explore underlying attributes to QoL. METHODS:
Semi-structure interviews were conducted at amedical center in southern Taiwan
from July 2010 to December 2010. Outpatients with defined diagnosis of IBS and
receivingmedical treatmentwere invited to participate, and a topic guidewas used
to ensure systematic coverage of attributes related to QoL. The interviews were
audiotaped and transcribed verbatim for framework analysis. RESULTS: The most
disturbing symptoms for 29 participantswere recurrent abdominal pain or discom-
fort, which affect the efficiency of work or study. In addition, the frequent bowel
movements reduce patient’s willingness to participate in social activities and jeop-
ardize their interpersonal relationship. Moreover, repeated inspections and medi-
cal visits during follow-ups also raise patients’ further concerns and worries on
health. Unsatisfied symptoms control was commonly stated by participants and
alternative managements such as homeopathic remedies, traditional Chinese
medicines, sports, and diet modifications were tried and considered being ineffec-
tive. Some participants with uncontrolled symptoms acknowledged their failure in
adhering to medical treatment due to the concerns of adverse drug reactions.
CONCLUSIONS: For patients with potentially moderate to severe IBS and consis-
tent medical treatments, the functional impairment was still tolerable yet intan-
gible (anxiety, worries) and social stress may have greater impacts on QoL. There-
fore, a capability approach may work better than the utility and functioning QoL
measure.
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